Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5′-nucleotidase

American Journal of Hematology

Volumn 88, Issue 12, 2013, Pages 1001-1006

  Falk, Ingrid Jakobsen ^a   Fyrberg, Anna ^a   Paul, Esbjörn ^b   Nahi, Hareth ^b   Hermanson, Monica ^c   Rosenquist, Richard ^c   Höglund, Martin ^d   Palmqvist, Lars ^e   Stockelberg, Dick ^f   Wei, Yuan ^f   Gréen, Henrik ^a,g,h   Lotfi, Kourosh ^a,i  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^h Linköping University Hospital ^*  (Sweden)

ⁱ LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; CYTARABINE; CYTIDINE DEAMINASE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA METHYLATION; DRUG SENSITIVITY; FEMALE; GENE FREQUENCY; GENE INSERTION; GENOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

5'-NUCLEOTIDASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYTARABINE; CYTIDINE DEAMINASE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDARUBICIN; KAPLAN-MEIER ESTIMATE; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TANDEM REPEAT SEQUENCES; TOPOISOMERASE I INHIBITORS; YOUNG ADULT;

EID: 84888026119     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23549     Document Type: Article

References (39)

1. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA 2002;52:363-371.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-2333.
3. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:89-99.
4. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
5. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-448.
6. Ghanem H, Tank N, Tabbara IA. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics. Am J Hematol 2012;87:69-77.
7. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
8. Kottaridis PD, Gale RE, Linch DC. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk Lymphoma 2003;44:905-913.
9. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 ITD in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-1759.
10. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2002;100:4372-4380.
11. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New Engl J Med 2005;352:254-266.
12. Renneville A, Boissel N, Gachard N, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 2009;113:5090-5093.
13. Veuger MJ, Honders MW, Spoelder HE, et al. Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines. Leuk Res 2003;27:445-453.
14. Galmarini CM, Cros E, Thomas X, et al. The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica 2005;90:1699-1701.
15. Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003;101:1270-1276.
16. Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 2009;10:1657-1674.
17. Yamauchi T, Negoro E, Kishi S, et al. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol 2009;77:1780-1786.
18. Galmarini CM, Thomas X, Graham K, et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol 2003;122:53-60.
19. Jordheim LP, Nguyen-Dumont T, Thomas X, et al. Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53. Drug Metab Dispos 2008;36:2419-2423.
20. Yue L, Saikawa Y, Ota K, et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003;13:29-38.
21. Kim SR, Saito Y, Maekawa K, et al. Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet 2008;23:379-384.
22. Mahlknecht U, Dransfeld CL, Bulut N, et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: Identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 2009;23:1929-1932.
23. Giovannetti E, Laan AC, Vasile E, et al. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008;27:720-725.
24. Wahlin A, Billstrom R, Bjor O, et al. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Eur J Haematol 2009;83:99-107.
25. Green H, Soderkvist P, Rosenberg P, et al. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci 2008;97:2045-2048.
26. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776-2784.
27. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-4335.
28. Sundman-Engberg B, Tidefelt U, Liliemark J, et al. Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo. Cancer Chemother Pharmacol 1990;25:252-256.
29. Sundman-Engberg B, Tidefelt U, Gruber A, et al. Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo. Leuk Res 1993;17:347-352.
30. Mollgard L, Tidefelt U, Sundman-Engberg B, et al. In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay. Leuk Res 2000;24:445-452.
31. Fitzgerald SM, Goyal RK, Osborne WR, et al. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet 2006;119:276-283.
32. Gilbert JA, Salavaggione OE, Ji Y, et al. Gemcitabine pharmacogenomics: Cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006;12:1794-1803.
33. Wong A, Soo RA, Yong WP, et al. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009;41:77-88.
34. Kirch HC, Schroder J, Hoppe H, et al. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998;26:421-425.
35. Anant S, Davidson NO. Hydrolytic nucleoside and nucleotide deamination, and genetic instability: A possible link between RNA-editing enzymes and cancer? Trends Mol Med 2003;9:147-152.
36. Kobayashi M, Aida M, Nagaoka H, et al. AID-induced decrease in topoisomerase 1 induces DNA structural alteration and DNA cleavage for class switch recombination. Proc Natl Acad Sci USA 2009;106:22375-22380.
37. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003;95:399-409.
38. Lemaire M, Momparler LF, Raynal NJ, et al. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 2009;63:411-416.
39. Lamba JK, Crews K, Pounds S, et al. Pharmacogenetics of deoxycytidine kinase: Identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007;323:935-945.